Minerva Neurosciences, Inc (NERV) Financial Statements (2024 and earlier)

Company Profile

Business Address 1601 TRAPELO ROAD
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments51,796,71135,978,19936,093,60640,220,00849,753,99854,946,711
Cash and cash equivalents51,796,71135,978,19936,093,60640,220,00849,753,99854,946,711
Restricted cash and investments100,000100,000100,000100,000100,000100,000
Prepaid expense329,153596,045848,1171,403,532184,821650,481
Other undisclosed current assets   3,117,2183,117,218  
Total current assets:52,225,86436,674,24440,158,94144,840,75850,038,81955,697,192
Noncurrent Assets
Property, plant and equipment13,60514,96616,326   
Intangible assets, net (including goodwill)14,869,39914,869,39914,869,39914,869,39914,869,39914,869,399
Goodwill14,869,39914,869,39914,869,39914,869,39914,869,39914,869,399
Other undisclosed noncurrent assets29,79736,18242,56748,95251,08051,080
Total noncurrent assets:14,912,80114,920,54714,928,29214,918,35114,920,47914,920,479
TOTAL ASSETS:67,138,66551,594,79155,087,23359,759,10964,959,29870,617,671
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,494,0571,505,3631,098,1423,290,0252,532,8702,131,564
Employee-related liabilities1,209,504827,856429,484
Accounts payable298,251960,998969,667532,8881,519,7291,586,168
Accrued liabilities1,195,806544,365128,4751,547,633185,285115,912
Other undisclosed current liabilities413,749996,298279,434(1,093,166)876,0581,116,122
Total current liabilities:1,907,8062,501,6611,377,5762,196,8593,408,9283,247,686
Noncurrent Liabilities
Other undisclosed noncurrent liabilities77,741,76075,711,30273,733,87671,808,09669,932,61468,106,115
Total noncurrent liabilities:77,741,76075,711,30273,733,87671,808,09669,932,61468,106,115
Total liabilities:79,649,56678,212,96375,111,45274,004,95573,341,54271,353,801
Equity
Equity, attributable to parent(12,510,901)(26,618,172)(20,024,219)(14,245,846)(8,382,244)(736,130)
Common stock6995345345345344,272
Additional paid in capital367,460,923347,161,781346,785,322345,837,638344,800,764343,725,426
Accumulated deficit(379,972,523)(373,780,487)(366,810,075)(360,084,018)(353,183,542)(344,465,828)
Total equity:(12,510,901)(26,618,172)(20,024,219)(14,245,846)(8,382,244)(736,130)
TOTAL LIABILITIES AND EQUITY:67,138,66551,594,79155,087,23359,759,10964,959,29870,617,671

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(4,519,995)(5,348,518)(5,069,731)(5,207,148)(6,965,189)(7,989,258)
Operating loss:(4,519,995)(5,348,518)(5,069,731)(5,207,148)(6,965,189)(7,989,258)
Nonoperating income358,417355,532269,454182,15473,9743,623
Investment income, nonoperating365,623364,218297,060180,09172,3787,417
Gain (loss), foreign currency transaction, before tax(7,206)(8,686)(27,606)2,0631,596(3,794)
Loss from continuing operations before equity method investments, income taxes:(4,161,578)(4,992,986)(4,800,277)(5,024,994)(6,891,215)(7,985,635)
Other undisclosed loss from continuing operations before income taxes   (7,406,555)   
Loss from continuing operations:(4,161,578)(4,992,986)(12,206,832)(5,024,994)(6,891,215)(7,985,635)
Loss before gain (loss) on sale of properties:(5,024,994)(6,891,215)(7,985,635)
Other undisclosed net income (loss)  (1,977,426)5,480,775  (1,778,794)
Net loss:(4,161,578)(6,970,412)(6,726,057)(5,024,994)(6,891,215)(9,764,429)
Other undisclosed net loss attributable to parent(2,030,458)  (1,875,482)(1,826,499) 
Net loss available to common stockholders, diluted:(6,192,036)(6,970,412)(6,726,057)(6,900,476)(8,717,714)(9,764,429)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(4,161,578)(6,970,412)(6,726,057)(5,024,994)(6,891,215)(9,764,429)
Comprehensive loss, net of tax, attributable to parent:(4,161,578)(6,970,412)(6,726,057)(5,024,994)(6,891,215)(9,764,429)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: